Antoine Capes

Oct 19, 2024 | onlinelibrary.wiley.com | Hôpital Saint-Antoine |AP-HP Paris France |Antoine Capes

Within the past decade, chimeric antigen receptor (CAR)-T-cell therapy has been established as a key treatment for relapsed/refractory B-cell malignancies.1 However, this breakthrough in terms of efficacy came with some specific toxicities such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).2, 3 In addition to CRS and ICANS, cytopenias are frequent after CAR-T-cell infusions. Rejeski et al.